Panobinostat (LBH589)

目录号:S1030 别名: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。

规格 价格 库存 购买数量  
RMB 731.86 现货
RMB 2189.52 现货
RMB 5485.18 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献52篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。
靶点
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外研究

LBH589诱导MOLT-4和Reh细胞凋亡,这种作用具有时间和剂量依赖性。而且,LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长,处理48小时,具有剂量依赖性。与对照组细胞相比,用LBH589处理的细胞,在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关,LBH589也降低c-Myc的表达水平,具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589(10 nM)处理Reh细胞,最初增强c-Myc的表达水平,之后一直降低c-Myc的表达水平。此外,LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下,LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。[1]此外, LBH589抑制非小细胞肺癌细胞系生长,如人类H1299,L55和A549,IC50分别为5,11和30 nM;间皮瘤细胞生长,如人类OK-6和 Ok-5,IC50分别为5和7 nM;及小细胞肺癌细胞系生长,如人类RG-1和LD-T,IC50分别为4和5 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NUHzSnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XTdlAuOTBizszN NXTS[nNwOC12IHS= M2XIUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVjmdVRqOjZ5MEK3PFQ>
HepG2 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6wMVExKM7:TR?= MXSwMVQh\A>? M1PnV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3jLNlI3PzB{N{i0
HT29 NWLMRXp5TnWwY4Tpc44hSXO|YYm= MX21NOKhdk1? NH;YSY4zPC15MjDo M{iwfIlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> NILSZXUzPjdyMke4OC=>
HepG2 NWqzXlNpTnWwY4Tpc44hSXO|YYm= NEL3[og2OMLibl2= MnvaNlQuPzJiaB?= MWHpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFI1yqCqwrC= M4r3RlI3PzB{N{i0
HCC827 NWTUS3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[1M|cvPS9zMDDuUS=> NGjpXWE4OsLiaB?= MmL6SG1UVw>? M{m0NYVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MWOyOlY4PTR6NB?=
A549  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzieG4yOC9zNT:yNEBvVQ>? MknOO|LDqGh? NYfVWGZFTE2VTx?= NXzZZVZW\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MmfRNlY3PzV2OES=
NCI-H460  MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTvSlB4OTBxMkCvN|Ahdk1? MljvO|LDqGh? MoX2SG1UVw>? MVnlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MXiyOlY4PTR6NB?=
J89GFP M1nPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKzXG05TE2VT9Mg NXLVdFZxTUN3ME20PU45PSEEsTCxNk43PSCwTR?= NEXyfZozPjV4M{W2PC=>
THP89GFP M1SyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXEUXNQyqB? NWPXSmFDTUN3ME2xPU4{PCEEsTC2MlQ{KG6P M2D2b|I3PTZ|NU[4
SK-NEP-1 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn0d3pYOC5yMfMAl|ExNjBizszN MVqyOEBp MkPBSG1UV8Li MXrJR|UxRTd4LkO0JI5O NF\C[FAzPjF5NkKxPS=>
G401 M3jmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH4b3p6OC5yMfMAl|ExNjBizszN Mnz3NlQhcA>? M2jNZmROW00EoB?= NGrF[|dKSzVyPUG0N{4xOiCwTR?= M{fzTlI3OTd4MkG5
SK-NEP-1 NWjBXlV1S2WubDDWbYFjcWyrdImgRZN{[Xl? M{e2bVUxKG6P NEL0[Ysy6oDVNDDk MmixSG1UV8Li MnnudoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz M4TpclI3OTd4MkG5
G401 Mm\ER4VtdCCYaXHibYxqfHliQYPzZZk> NVvXTZJ2PTBibl2= NFPtZmky6oDVNDDk MoSzSG1UV8Li NGLGRYlz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M{Gxe|I3OTd4MkG5
SK-NEP-1 M2Xn[2Fxd3C2b4Ppd{BCe3OjeR?= MlryOVAwOTByIH7N M1XWTlI1KGh? NGnod41FVVORwrC= NVWzfoE6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHvWSYczPjF5NkKxPS=>
G401 NXrGTpV[SXCxcITvd4l{KEG|c3H5 NEj3RnQ2OC9zMECgcm0> NETTTHczPCCq NYjacFdPTE2VT9Mg NEnqUnNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYSyOlE4PjJzOR?=
SK-NEP-1 M1LGbWZ2dmO2aX;uJGF{e2G7 NYXoemFIPTBxMUCwJI5O NIHIUJgzPCCq NFfGd3BFVVORwrC= MU\zbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v M1;XU|I3OTd4MkG5
G401 M1SyS2Z2dmO2aX;uJGF{e2G7 NX71dHR3PTBxMUCwJI5O MX[yOEBp MY\EUXNQyqB? MVTzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v M4HseFI3OTd4MkG5
SK-NEP-1 MV7GeY5kfGmxbjDBd5NigQ>? M1TUW|UxNzFyMDDuUS=> NYfwSXA6OjRiaB?= MXfEUXNQyqB? MYPpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> M2\3PVI3OTd4MkG5
G401 Mn:zSpVv[3Srb36gRZN{[Xl? Ml;1OVAwOTByIH7N NU\JVFFEOjRiaB?= MUTEUXNQyqB? M4XhNIlv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh M{TyZ|I3OTd4MkG5
RPMI 8226 M{D0XWNmdGxiU4Xyeol3[WxiQYPzZZk> NWDtNVhoOi92L{[gcm0> M2XOXFQ56oDLaB?= MULpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NV;sVFVqOjZyMECyPVI>
OPM2 NEjB[HFE\WyuIGP1dpZqfmGuIFHzd4F6 MmfkNk81NzZibl2= Mnr1OFjjiImq Mnv5bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NITOeFEzPjByMEK5Ni=>
U266 M1PrfGNmdGxiU4Xyeol3[WxiQYPzZZk> NEDWNIgzNzRxNjDuUS=> NFvNcpg1QOLCiXi= NFjP[HNqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MoDBNlYxODB{OUK=
H929 MmTsR4VtdCCVdYL2bZZidCCDc4PhfS=> M2\2bFIwPC94IH7N MVK0PQKBkWh? NVrURmpIcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M2DtZ|I3ODByMkmy
RPMI 8226  MU\BdI9xfG:|aYOgRZN{[Xl? NHnhN3c16oDLbl2= NEDGSVYzPC92ODDo M2\HWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MVGyOlAxODJ7Mh?=
HCC827 NHXZ[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxNEBvVQ>? MnHUOFghcA>? MUnEUXNQ NX3KXZNT\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= NF22OoYzPTl2NE[xOy=>
NCI-H23 NVPrT5k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIOW17OTBibl2= MoHKOFghcA>? NVq1ZlhNTE2VTx?= MWrlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? MX6yOVk1PDZzNx?=
AML3 Mm\aSpVv[3Srb36gRZN{[Xl? M3P5S|AuOSEQvF2= MljzNlTDqGh? M4LCPIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUCyOVYyOjl2MR?=
ML-1 MXrGeY5kfGmxbjDBd5NigQ>? M4DwVFAuOSEQvF2= NYDnPWtROjUEoHi= NVf4S25pcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3n3Z|I2PjF{OUSx
RPMI-8226vr10  MWDGeY5kfGmxbjDBd5NigQ>? MXywMVEh|ryP M4PmTVI1yqCq NVTWWHc5cW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUiyT2ZTOjV4MUK5OFE>
ML-1 MmfrSpVv[3Srb36gRZN{[Xl? NVr1NVQ4OSEQvF2= NYf4SWJNOjUEoHi= MUPpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFQu\m:uZB?= MoK0NlU3OTJ7NEG=
RPMI-8226vr10  NHvxXFJHfW6ldHnvckBCe3OjeR?= MoDONUDPxE1? MYSyOOKhcA>? M2DXfYlv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ> M2rCVFI2PjF{OUSx
SK-N-BE (2) M4m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrqe|gzPOLCiXi= MVnJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? Moi1NlU{ODh7MU[=
SK-N-BE (2), PAN  MK M3;FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzBeGczPOLCiXi= MkXHTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P M4PPVVI2OzB6OUG2
SK-N-BE (2), MK  PAN NFX4RWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HhfVI16oDLaB?= NIH1NFlKSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N MoqwNlU{ODh7MU[=
SK-N-AS NFzDdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfOUZhUOjUkgJno NYPsenY5UUN3ME2zO{4y6oDLwsJihKkzNjRibl2= MoDDNlU{ODh7MU[=
SK-N-DZ M1\5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrhOJUzPOLCiXi= MnuyTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? M4L4d|I2OzB6OUG2
Caki-1 NITlPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HUVVExNzJ3L{WwJI5O NIHTUJM1QCCq M1u5cIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M{XjXlI2Ojd7MUmx
ACHN Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvIVJEyOC9{NT:1NEBvVQ>? M1XIblQ5KGh? NYPwdlM2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny MUeyOVI4QTF7MR?=
769-P MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNE8zPS93MDDuUS=> NHHwUmw1QCCq M3PTN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MoqxNlUzPzlzOUG=
786-O  MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYiwSlBlOTBxMkWvOVAhdk1? NY\2PI5GPDhiaB?= MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NYq1RYI6OjV{N{mxPVE>
Caki-1 NXnMNXhDSXCxcITvd4l{KEG|c3H5 MXG1NEBvVQ>? M2T5N|Q5KGh? NVf0dI5pcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= Mn\tNlUzPzlzOUG=
ACHN M1n6[WFxd3C2b4Ppd{BCe3OjeR?= M2fOZVUxKG6P NV73cXVTPDhiaB?= NUHuPIEzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NGmy[3QzPTJ5OUG5NS=>
769-P Mn\aRZBweHSxc3nzJGF{e2G7 MkPGOVAhdk1? M33WVlQ5KGh? NULSOGxKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MX:yOVI4QTF7MR?=
786-O  NGDH[WRCeG:ydH;zbZMhSXO|YYm= M1\LNlUxKG6P NEfhV4Q1QCCq MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MUOyOVI4QTF7MR?=
Caki-1 NFXzW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HJR|I2NzVyIH7N Mn;OOFghcA>? NGT4[GVFVVOR MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk M1LUWlI2OTd4M{W0
ACHN Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LZZVI2NzVyIH7N NIrNWFk1QCCq NIjCSJBFVVOR NILBV3JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni MV2yOVE4PjN3NB?=
769-P Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jqTFI2NzVyIH7N MlT0OFghcA>? NVzONXBRTE2VTx?= NYW2d|JPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> M3\RdFI2OTd4M{W0
Caki-1 NXWwXG9NS2:ub375JGZwem2jdHnvckBCe3OjeR?= NHHmR5k2OCCwTR?= NV\ROY8zPy1zNDDk MULEUXNQ M2jQO5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh M3rwdVI2OTd4M{W0
ACHN NF;p[XVEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NYe4O5pRPTBibl2= M2r0OFcuOTRiZB?= NF\MUXFFVVOR MULzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> M2DCZ|I2OTd4M{W0
769-P Ml;CR49td267IF\vdo1ifGmxbjDBd5NigQ>? MmPrOVAhdk1? M{\4TVcuOTRiZB?= M3SzR2ROW09? NFXVfWt{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? NGPXRZIzPTF5NkO1OC=>
Caki-1 NEHocphCeG:ydH;zbZMhSXO|YYm= NFHJbo42OCCwTR?= MmXGOFghcA>? NY[zfFd{TE2VTx?= M4LZd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml;PNlUyPzZ|NUS=
ACHN M1:wemFxd3C2b4Ppd{BCe3OjeR?= NGfuV2U2OCCwTR?= NWfIR2s4PDhiaB?= NGTGPGFFVVOR MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1f2fVI2OTd4M{W0
769-P Mkj1RZBweHSxc3nzJGF{e2G7 NGDkdlY2OCCwTR?= MVi0PEBp NEHndZNFVVOR NVntSpRlcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M376TVI2OTd4M{W0
MDA-MB-231 MVTNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> M1TNd|ExyqCwTR?= MUWzxsBl MV\EUXNQ Mnr3ZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MnPmNlQ5OTB2OUe=
BT-549 NV\jWpVGVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MlTKNVDDqG6P NXf1OpFtO8LiZB?= M1XIcmROW09? MXHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? NGrt[GUzPDhzMES5Oy=>
MCF-7  MoT5UY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MnG2NVDDqG6P MoqyN:Kh\A>? M1\GfmROW09? M3;mc4FtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MmXlNlQ5OTB2OUe=
MCF-7 MVzGeY5kfGmxbjDBd5NigQ>? M4jxW|UuPTBibl2= NHfHS28zPCCq NELQcmNFVVOR MVjy[YR2[2WmIITo[UBt\X[nbDDv[kBmgHC{ZYPzbY9vKG:oIFXS{tEtKFCUIHHu[EBHd3iDMdMg NVPNN2xjOjR|Nk[0NFc>
CTS NIX2eo5CeG:ydH;zbZMhSXO|YYm= MYWw5qCUPDBibl5CpC=> NH:zNJQ1QCCq Mon4bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFuyWFkzPDJ2NESyPS=>
OCI-AML3  NWPuVopoSXCxcITvd4l{KEG|c3H5 MmrINQKBmzRyIH7NxsA> NWLFVoU4PDhiaB?= M4PxWIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmC2NlQzPDR2Mkm=
U937 M4DCVGFxd3C2b4Ppd{BCe3OjeR?= NGfSbGYx6oDVNECgcm3DqA>? NXnBWXFIPDhiaB?= MX3pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mly1NlQzPDR2Mkm=
PC3 MnPCRZBweHSxc3nzJGF{e2G7 MWiwMVExOCCwTR?= M2DP[FI1NzR6IHi= MoXybY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEDkb|kzPDF4M{KzNC=>
PC3-AR NV;0VXhRSXCxcITvd4l{KEG|c3H5 NWjs[ZFtOC1zMECgcm0> NWXaOXo3OjRxNEigbC=> MXTpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnXSNlQyPjN{M{C=
PC3 M364UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVewMVExOCCwTR?= NXrUbo5QOjRxNEigbC=> MV;pcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v NXvub3hTOjRzNkOyN|A>
PC3-AR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Tyd|AuOTByIH7N Mnz6NlQwPDhiaB?= MlTpbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{LNJJBp[XOn MYOyOFE3OzJ|MB?=
PC3 M{XNXmZ2dmO2aX;uJGF{e2G7 MWGwMVExOCCwTR?= M1fSflI1KGh? NES5bXB{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> NGD3OmMzPDF4M{KzNC=>
PC3-AR NIrqUmlHfW6ldHnvckBCe3OjeR?= MV6wMVExOCCwTR?= MnPMNlQhcA>? M1G5XpN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu Mk\pNlQyPjN{M{C=
OS-RC-2 NWH4ZpE6S2WubDDWbYFjcWyrdImgRZN{[Xl? M1LyPVAuOTByMDDuUS=> MYqyOE81QC95MjDo MV3EUXNQ M3\veYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlP6NlQyPDR5M{e=
OS-RC-2 NFn2UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnBflNxPTBibl2= NUjhXYVxPDhiaB?= NV:3NFc{TE2VTx?= M4j0cIlv\HWlZYOgS|IwVSCjcoLld5Q> MU[yOFE1PDd|Nx?=
OS-RC-2 MWTBdI9xfG:|aYOgRZN{[Xl? MX61NEBvVQ>? M4PscVQ5KGh? M2DUe2ROW09? NIr2cndqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NX3GXnZ4OjRzNES3N|c>
SK-N-AS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj6TIIx6oDVOECgcm0> NHzmU4I1QCCq MmH0TWM2OD1{Nz60JI5O NYnjdZp{OjRyOUi3PVk>
SK-N-DZ NV7GVo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWw5qCUQDBibl2= NWLtOYY5PDhiaB?= MmLPTWM2OD1{MT65JI5O NIW0UJQzPDB7OEe5PS=>
SK-N-SH NXjFUo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6w5qCUQDBibl2= M4TqUVQ5KGh? NHXVXJFKSzVyPUeyMlMhdk1? Mk[0NlQxQTh5OUm=
SK-N-BE NWDIPJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTETmRROOLCk{iwJI5O Mn;TOFghcA>? MWPJR|UxRTd3LkSgcm0> NGHmeJczPDB7OEe5PS=>
SK-N-AS Mn7mRZBweHSxc3nzJGF{e2G7 MWSw5qCUQDBibl2= MXW0PEBp NHvrTZRxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M3u3UFI1ODl6N{m5
SK-N-DZ NGmzNpBCeG:ydH;zbZMhSXO|YYm= NW\6dWpbOOLCk{iwJI5O M1raRVQ5KGh? M{fpS5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NUfjVG45OjRyOUi3PVk>
SK-N-SH NYHwPYo5SXCxcITvd4l{KEG|c3H5 Ml\INQKBmzRyIH7N NI\n[GI1QCCq NWfFSId[eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NUHNfpplOjRyOUi3PVk>
SK-N-BE MW\BdI9xfG:|aYOgRZN{[Xl? NFPHe2Yx6oDVNECgcm0> Mkf1OFghcA>? MmHZdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MUiyOFA6QDd7OR?=
SK-N-AS MmrkSpVv[3Srb36gRZN{[Xl? M1TnW|DjiJN6MDDuUS=> NY[ze4l{PDhiaB?= NGWwN3VqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR M3zRVVI1ODl6N{m5
SK-N-DZ MlLOSpVv[3Srb36gRZN{[Xl? NIPMTFkx6oDVOECgcm0> M1z1WVQ5KGh? MkC3bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NYrUNGc3OjRyOUi3PVk>
SK-N-SH NH;FbVFHfW6ldHnvckBCe3OjeR?= NVX1Xpc3OOLCk{SwJI5O M4HKV|Q5KGh? MVHpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NILwVoYzPDB7OEe5PS=>
SK-N-BE MojHSpVv[3Srb36gRZN{[Xl? NWXLbVR6OOLCk{SwJI5O NIj4[Wc1QCCq MVvpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NFLPWYozPDB7OEe5PS=>
HCC-LM3 M2ntfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\LVHoyNTFyMECgcm0> NH25SXMzPC92OD:3NkBp MULEUXNQ M3;wfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHTEXIczPDB7M{m1Oi=>
HepG2 NX7vOpJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPVNU0yODByIH7N MV6yOE81QC95MjDo MnrvSG1UVw>? MlGwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2m1RVI1ODl|OUW2
SMMC-7721 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjsOpVqOS1zMECwJI5O MXiyOE81QC95MjDo NF65c|NFVVOR M2\hXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF;idG0zPDB7M{m1Oi=>
HCC-LM3 M2\ocGFxd3C2b4Ppd{BCe3OjeR?= NG\sOmE2OCCwTR?= NUHGbWdvPDhiaB?= MVvEUXNQ M1r1Oolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NXjZS3JVOjRyOUO5OVY>
HepG2 MonlRZBweHSxc3nzJGF{e2G7 Mny4OVAhdk1? NWDiVldlPDhiaB?= NGTDbY5FVVOR NV:2WnBXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MWKyOFA6Ozl3Nh?=
SMMC-7721 M3;FbmFxd3C2b4Ppd{BCe3OjeR?= MUC1NEBvVQ>? MVS0PEBp NIPXcGlFVVOR M{HaXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 M{jW[FI1ODl|OUW2
HCC-LM3 MUjGeY5kfGmxbjDBd5NigQ>? NEPkR|E2OC9zMECgcm0> MWmyOEBp NUHYNohCTE2VTx?= M{jmSIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= M3\MTlI1ODl|OUW2
HepG2 NIHlN2VHfW6ldHnvckBCe3OjeR?= NYOyN4JjPTBxMUCwJI5O MWKyOEBp MULEUXNQ NGjxdVVl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NEPlfYwzPDB7M{m1Oi=>
SMMC-7721 MnjYSpVv[3Srb36gRZN{[Xl? NXLWZ4dtPTBxMUCwJI5O M4XTVlI1KGh? MkK2SG1UVw>? M3\ZT4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= NUjiU2tiOjRyOUO5OVY>
HCC-LM3 NIX2XIpHfW6ldHnvckBCe3OjeR?= MXq1NE8yODBibl2= NXXqbJV[OjRiaB?= Ml3BSG1UVw>? NFW4fGtld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MkDINlQxQTN7NU[=
HepG2 MknOSpVv[3Srb36gRZN{[Xl? M2rs[VUxNzFyMDDuUS=> Mn3kNlQhcA>? NEOwZWtFVVOR MnLI[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? NH7WSYYzPDB7M{m1Oi=>
SMMC-7721 MVzGeY5kfGmxbjDBd5NigQ>? MmrkOVAwOTByIH7N NEPUS2EzPCCq M2HkVGROW09? MYfkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MYOyOFA6Ozl3Nh?=
FaDu NEXER29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fUSFExOOLChX7N NUC5VoZJQC9zMD:xNkBp NXPRVVlm\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl MkHENlQxOjZ2OEK=
FaDu MXTGeY5kfGmxbjDBd5NigQ>? MkfyNVAx6oDHbl2= M4CzZlIwPC96L{GyJIg> MlK1bY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? M1LW[|I1ODJ4NEiy
PC-3  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PIUVAuOTBizszN NGrPO3IzPC92OD:3NkBp M2\RPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWCyN|k6OTJzNh?=
LNCaP NFHzSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiwMVUh|ryP MlTKNlQwPDhxN{KgbC=> MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHfiNo4zOzl7MUKxOi=>
RWPE-1  NUnrUJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnyRZVrOC1{MDFOwG0> MoPNNlQwPDhxN{KgbC=> MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4\CZVI{QTlzMkG2
Capan-1 MVrGeY5kfGmxbjDBd5NigQ>? NUHBPIpFOjVxNUCvNVAxKG6P NWe1dVRsQC9{ND:0PEBp M2j2OGROW09? M2jTUYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= M4q1WVI{QTJ{OEi2
L3.6pl NGnyW3RHfW6ldHnvckBCe3OjeR?= MkXENlUwPTBxMUCwJI5O M3i4fVgwOjRxNEigbC=> M1TpeWROW09? MUXkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p M2jtSVI{QTJ{OEi2
CFPAC-1  NE\R[VhHfW6ldHnvckBCe3OjeR?= MVWyOU82OC9zMECgcm0> M1nJS|gwOjRxNEigbC=> MmPHSG1UVw>? MVXkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MUmyN|kzOjh6Nh?=
Capan-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K3NVI2NzVyL{GwNEBvVQ>? NGnWNZk1QCCq NWXUbHdxTE2VTx?= MV7y[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXW1R|VuOjN7MkK4PFY>
L3.6pl M2Ljfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOyOU82OC9zMECgcm0> Mo\tOFghcA>? NFTNOWpFVVOR MoiwdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1fGcVI{QTJ{OEi2
CFPAC-1  MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjYOWVxOjVxNUCvNVAxKG6P NUW2b5p4PDhiaB?= NH7OS5hFVVOR NVPwWHBiemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnfPNlM6OjJ6OE[=
Capan-1 M2OwR2Fxd3C2b4Ppd{BCe3OjeR?= MUSyOU82OC9zMECgcm0> NG\5PZE1QCCq MnnaSG1UVw>? Mo\ubY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX[yN|kzOjh6Nh?=
L3.6pl NXfGWJBISXCxcITvd4l{KEG|c3H5 NYXhPYY4OjVxNUCvNVAxKG6P NFPYZ|U1QCCq NV7xNmRKTE2VTx?= NFqxWHdqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NV\BRmhNOjN7MkK4PFY>
CFPAC-1  MV;BdI9xfG:|aYOgRZN{[Xl? NXy1bHBGOjVxNUCvNVAxKG6P MYG0PEBp MX;EUXNQ M2rlcYlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH\VbGozOzl{Mki4Oi=>
HN22 NH3NVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMVIxKG6P NYnQSFA3OjRxNEigbC=> MkfWSG1UVw>? M3TKXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> M4[2NVI{QDd5MkO1
HSC4  NHrsU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoftNE0zOCCwTR?= NHXuSWkzPC92ODDo NFyzRpNFVVOR MkTlbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NI[yeVMzOzh5N{KzOS=>
HN22 M3LpTmFxd3C2b4Ppd{BCe3OjeR?= M{\PelAuOjBibl2= MWG0PEBp NFz6VFdFVVOR MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnXiNlM5Pzd{M{W=
HSC4  MnnvRZBweHSxc3nzJGF{e2G7 NHPBZoUxNTJyIH7N MoDpOFghcA>? NVHUd49KTE2VTx?= MoXWbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUCwc4RwOjN6N{eyN|U>
HN22 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i5dVAuOjBibl2= NFradXI1QCCq M4PVXWROW09? MUjpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= M2XkPVI{QDd5MkO1
HSC4  M2XvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMVIxKG6P MXO0PEBp NVvvcnRFTE2VTx?= NGfYe3NqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> M4HSZlI{QDd5MkO1
HN22 MnnwSpVv[3Srb36gRZN{[Xl? MmOzNE0zOCCwTR?= MUm0PEBp NF\PPXlFVVOR MojKd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg NETiOngzOzh5N{KzOS=>
HSC4  M1ToUmZ2dmO2aX;uJGF{e2G7 NGHSdpYxNTJyIH7N NHzRTJQ1QCCq MmTHSG1UVw>? M1jVd5N2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> MVeyN|g4PzJ|NR?=
Cal62 NFjTPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrhTHpKSzVyPUOzJOKyKDRibl2= M3i0XlI{QDJ2ME[0
Hth7 NIHLVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjEW2VKSzVyPUG1JOKyKDJibl2= MXWyN|gzPDB4NB?=
Hth83 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrMNGxKSzVyPUO0JOKyKDVibl2= MoC3NlM5OjRyNkS=
C643 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdzINMxJFExKG6P M3fsV|I{QDJ2ME[0
SW1736 NUDtZlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrNOHVKSzVyPUO1JOKyKDhibl2= NXfXRVlZOjN6MkSwOlQ>
T241 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjFN5VKSzVyPU[1JOKyKDdibl2= MX6yN|gzPDB4NB?=
T351 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGwTWM2OD13MDFCtUAyOCCwTR?= MoXsNlM5OjRyNkS=
BHP2-7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\nV3FKSzVyPUO3JOKyKDZibl2= NELrTnkzOzh{NEC2OC=>
T238 M2DoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TrfWlEPTB;MTy1NFAhyrFiMkCwJI5O NVn6PXBKOjN6MkSwOlQ>
HCT8 M3H4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v0fVczKGh? M3jCRmROW09? MYjJR|UxRTF{LkpihKnDueLCiUGuPUBvVQ>? MlrpNlMzQTl|OEi=
H630 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoixO|IhcA>? MoH6SG1UVw>? NFm4bVhKSzVyPUGyMlTjiIoEsfMAjVMvOSCwTR?= MVuyN|I6QTN6OB?=
cH630 5-FU-res MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:xN4k4OiCq NVXYR|hITE2VTx?= M{jnZmlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P MWeyN|I6QTN6OB?=
HCT116 M4TYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvCcmM4OiCq MYnEUXNQ M4DwW2lEPTB;MUCuO-KBkcLz4pEJNk4zKG6P M2XkfFI{Ojl7M{i4
HCT116 p53−/− M3vFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\WfVczKGh? NVH6b5FZTE2VTx?= Mn7VTWM2OD16LkdihKnDueLCiUGuO{BvVQ>? Mo[3NlMzQTl|OEi=
dHCT116 p21−/− NWTUNHp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fVeVczKGh? M3i3PWROW09? NG\EXnJKSzVyPUWuPgKBkcLz4pEJNU4{KG6P M3vJb|I{Ojl7M{i4
HT29 NF\qZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiZ|czKGh? MlHSSG1UVw>? NVSyNZBnUUN3ME2xOk4{6oDLwsJihKkzNjNibl2= MWmyN|I6QTN6OB?=
LoVo NXj1V2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLiZoo{PzJiaB?= M1XHVmROW09? NFHBcJFKSzVyPUWuNgKBkcLz4pEJNE43KG6P MVmyN|I6QTN6OB?=
RKO NWLQOohnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW3NkBp NFSzO2pFVVOR Mn6xTWM2OD15LkpihKnDueLCiUKuNkBvVQ>? MWWyN|I6QTN6OB?=
SW480 NF73NHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LEflczKGh? M{\mXGROW09? M{LMb2lEPTB;MUeuOgKBkcLz4pEJNE45KG6P NHjqVIczOzJ7OUO4PC=>
eSW620 NULLZ|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;vVVczKGh? NGHQdppFVVOR M3nhTGlEPTB;OT6x5qCKyrIkgJmyMlEhdk1? NET1foYzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内研究 LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长,与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多,说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射,每周持续5天,导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比,LBH589作用于H526衍生的肿瘤下降53%,作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%,作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下,LBH589 作用于NSCLC和Meso衍生的移植瘤,导致SCLC衍生的肿瘤中有两种衰退,伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm3降低到实验结束时的116 mm3,RG-1衍生的平均肿瘤尺寸从实验开始时的185mm3降低到实验结束时的86 mm3[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: MOLT-4细胞和Reh(前体B细胞)
  • Concentrations: 50 nM
  • Incubation Time: 48小时
  • Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色,然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×104个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比,根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带10×106个M30细胞或5×106个A549细胞的SCID鼠
  • Formulation: 溶于水的5%葡萄糖
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 349.43
化学式

C21H23N3O2

CAS号 404950-80-7
稳定性 powder
in solvent
别名 NVP-LBH589

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Panobinostat (LBH589) | Panobinostat (LBH589)供应商 | 采购Panobinostat (LBH589) | Panobinostat (LBH589)价格 | Panobinostat (LBH589)生产 | 订购Panobinostat (LBH589) | Panobinostat (LBH589)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID